What is the Fiscal Year for IMMUTEP?
Date: November 13, 2026
IMMUTEP's current fiscal year starts on July 1, 2026, and ends on June 30, 2027. Their current quarter is Q2, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
July 1, 2026
Fiscal Year End
June 30, 2027
Current Quarter
Q2
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jul 1, 2026 – Sep 30, 2026
Q2
Oct 1, 2026 – Dec 31, 2026
Q3
Jan 1, 2027 – Mar 31, 2027
Q4
Apr 1, 2027 – Jun 30, 2027
Company Information
Headquarters
Sydney, NSW
Industry
Biotechnology Research
Stock Symbol
IMMP
Website
https://immutep.comDescription
Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. Its lead clinical candidate in oncology is eftilagimod alfa, a proprietary soluble LAG-3 protein and MHC Class II agonist that activates the immune system to fight cancer. In autoimmune diseases, Immutep's IMP761 is the world's first LAG-3 agonist antibody designed to target the underlying causes of autoimmune diseases. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. For more information, please visit www.immutep.com.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like IMMUTEP and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.